Injectable acellular matrix particle implant as well as preparation method and application thereof

Through independently packaged and separately sterilized decellularized matrix particles and suspensions, combined with the formulation of glycerol and sodium hyaluronate, the biocompatibility and dispersion of the injected implants is solved, achieving long-term repair and micro-microscopy The effect of innovating injection is suitable for large-scale production and clinical use.

CN119034010APending Publication Date: 2024-11-29SHANGHAI BAIYIYUAN BIOENGINEERING CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411175981.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-24
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing injectable implants have problems such as insufficient biocompatibility in the field of biomedical materials, difficulty in achieving long-term repair, and easy to cause inflammation and allergic reactions, and the decellularized matrix particles are unevenly dispersed and easily aggregated in the suspension agent. , affects the effectiveness and safety of the injection.

Method used

Using independently packaged and separately sterilized decellular matrix particles and suspension agents, through appropriate sterilization methods and suspension formulations, ensure that the particles are dispersed uniformly and stable when mixed before injection, and adjust the particles using glycerol and sodium hyaluronate. The dispersibility and viscoelasticity are suitable for injection of small diameter needles.

Benefits of technology

It has achieved biocompatible decellularized matrix microparticle implantation agent, which has long-term repair effect, reduces inflammatory response, ensures minimally invasiveness and dispersive stability of injection, and is suitable for large-scale production and clinical use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119034010A_ABST
    Figure CN119034010A_ABST
Patent Text Reader

Abstract

The invention relates to an injectable acellular matrix particle implant and a preparation method thereof, and relates to the technical field of biomedical materials. The decellularized matrix particle implant is prepared from decellularized matrix particles and a suspending aid, wherein the concentration ratio of the decellularized matrix particles to the suspending aid is (35mg-200mg): 1ml. The acellular matrix particles are prepared by decellularizing and granulating the submucosa of the small intestine of the pig. And the suspending aid contains glycerol with the concentration of 0.2%-1.0% and sodium hyaluronate with the concentration of 0.2%-0.5%. The acellular matrix particle implant has the advantages of good biocompatibility, natural biological components, structure and viscoelasticity, difficult displacement after implantation, long maintenance time, endogenous induction regeneration, good repair effect, minimally invasive injection (proper particle size, good dispersion uniformity and dispersion stability), good biocompatibility and good biocompatibility, and can be used for preparing the implant. The method is suitable for micro-shaping or repairing of human tissues.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] [Technical Field] The present invention relates to the field of biomedical materials, and specifically to an acellular matrix microparticle implant and a preparation method and use thereof. [Background technology]

[0002] With the development of society, the improvement of people's living standards and the popularization of micro-plastic surgery in recent years, the application of injectable implant materials has greatly increased in demand both internationally and domestically. In the repair and treatment of trauma, disease or congenital malformations and cosmetic surgery (such as repair and treatment of maxillofacial soft tissue defects, rhinoplasty and chin augmentation), it has gradually shown its unique advantages of less trauma and faster recovery, and has broad application prospects.

[0003] An ideal injectable implant should have good biocompatibility (safety), natural and long-lasting repair effect (good effect), easy injection and removal (simple), short recovery time (minimally invasive), etc. However, no ideal injectable implant has been developed so far.

[0004] At present, injectable implants at home and abroad can be divided into the following types according to their material types:

[0005] (1) Synthetic polymer materials, such as poly-L-lactic acid (PLLA), polycaprolactone (PCL), hydroxyapatite (CaHA) and PMMA (polymethyl methacrylate). These materials degrade slowly and can stimulate the body's own collagen regeneration to play a filling role. However, the collagen stimulated and generated is disordered pathological fibrotic tissue, and there are safety risks such as inducing long-term chronic inflammation and forming tissue cysts, which seriously restricts its development.

[0006] (2) Cross-linked hyaluronic acid products. This type of product currently has the largest market share, but after years of use, its shortcomings have gradually become apparent. For example, when injected into the tissue gap, it mainly plays a space-occupying effect and cannot induce autologous tissue regeneration. As the cross-linked hyaluronic acid degrades, tissue cavities are easily formed at the injection site, aggravating skin loosening. Therefore, multiple injections are required. However, multiple supplementary injections can easily lead to facial stiffness and wrinkling, and may cause excessive exposure of residual cross-linking agent and induce delayed allergic reactions.

[0007] (3) Collagen: The products currently on the market are type I collagen purified from bovine Achilles tendon or pig skin. Common disadvantages include: rapid degradation, short duration of action, weak induction of collagen fiber regeneration, the need for repeated injections, and possible complications such as allergic reactions.

[0008] (4) Decellularized matrix is ​​an extracellular matrix (ECM) material after immunogenic substances are removed by decellularization technology. This type of product has been widely used in the field of tissue engineering and clinical regenerative medicine, such as for the repair and reconstruction of heart valves, blood vessels, nerves, tendons, bones, cartilage, skin, esophagus, trachea, abdominal wall, and many other tissues. Studies have shown that the tissue repair and reconstruction effect of decellularized matrix is ​​closely related to the material tissue source and decellularization process. Among them, the decellularized matrix derived from porcine small intestinal submucosa (SIS) and human placenta has more complex and complete ECM components and structures. If prepared by appropriate decellularization process, the obtained material can achieve endogenous induced regeneration, thereby exerting better tissue repair, regeneration, and remodeling effects. Among the two raw materials, porcine SIS and human placenta, porcine SIS has the advantages of being easier to obtain, having more sources, no ethical issues, and low risk of virus transmission, and is more feasible for large-scale production. A large number of studies have shown that using porcine SIS as a raw material and adopting an appropriate decellularization process, the decellularized matrix with less immunogenic substances and good ECM components and structure can achieve endogenous induced regeneration.

[0009] SIS decellularized matrix, with its unique material advantages, is used as an injectable implant, and will be superior to other injectable materials currently on the market with its natural, firm, and durable features. However, when decellularized matrix materials are used as injectable implants, they must be provided in microparticle form, such as the allogeneic decellularized dermal microparticles Cymetra approved by the US FDA for marketing. Before use, they must be mixed with a suspending agent before being injected into the body. However, it is difficult to ensure the uniformity and stability of the suspension, as well as the patency of the injection needle when the microparticles are mixed with the suspending agent.

[0010] It can be seen that among the above-mentioned injectable implant materials, SIS decellularized matrix material is one of the most promising injectable materials at present, but there are still many technical difficulties in preparing it into products, as follows:

[0011] (1) It is difficult to find a suitable decellularization process. An ideal decellularization process can effectively remove immunogenic substances while ensuring that the ECM components and structures are relatively intact. It can also allow the decellularized matrix to retain the original viscoelasticity of the ECM, and ultimately enable the decellularized matrix to safely and effectively induce endogenous regeneration after being implanted in the body.

[0012] (2) The acellular matrix particles are irregular in shape and are prone to aggregation and precipitation in the suspending agent. If they are mixed with a conventional suspending agent and then injected, the dispersion is uneven and unstable, resulting in: ① Inconsistent injection concentration, affecting effectiveness; ② Needle clogging. If the injector pushes too hard, it is easy to cause excessive local injection volume, resulting in subcutaneous nodules and bulging. The injection dose is difficult to accurately control, seriously affecting the effectiveness and safety of the injection; ③ Needle clogging requires repeated needle replacement, which is inconvenient to operate.

[0013] (3) After the decellularized matrix particles and the suspending agent are mixed, if the fluidity is too high, the implant will be easily displaced after entering the body. (4) When the mixture of the decellularized matrix particles and the suspending agent is packaged, sterilized, stored and transported together, it is difficult to choose the appropriate sterilization method: ① If ethylene oxide sterilization is selected, it is difficult for ethylene oxide to enter the liquid, resulting in incomplete sterilization; ② If cobalt 60 or electron beam radiation sterilization is selected, the collagen component of the decellularized matrix particles will be cross-linked and the glycosaminoglycan component will be degraded in the liquid, resulting in the particles becoming hard and failing to achieve the physiological viscoelasticity of the ECM, which affects the clinical effect, and is prone to sedimentation, which affects injectability; ③ If moist heat high temperature sterilization is selected, the decellularized matrix structure will be severely damaged and denatured, which affects the clinical effect.

[0014] In short, how to choose a suitable decellularization process, how to ensure that the decellularized matrix particles have uniform and stable dispersion in the suspension agent (involving the minimally invasive injectability of the particles), cohesion (involving whether they are prone to displacement after implantation in the body), and how to choose a sterilization method (involving whether the implant retains the original viscoelasticity of the ECM) are still issues that plague various companies and research institutions.

[0015] Publication No. CN 1718249A discloses a method for preparing an injectable soft tissue biofiller material, which uses pig skin as a raw material, decellularizes, and processes it into 0.3-0.5 mm particles, adds 5-10 ml of PBS preservation solution per 3 g of particles, packs them in PVC bags, and sterilizes them by radiation with cobalt 60. The particles prepared in this patent have problems such as too large diameter (0.3-0.5 mm), too high concentration (300 mg-600 mg / ml), poor dispersion of PBS on particles, and increased hardness of particles after being irradiated in the solution, so it is impossible to use a needle with a smaller diameter for injection, and it is difficult to make a minimally invasive injectable product.

[0016] Publication number CN 101366978 A discloses a rapidly molded injectable microparticle tissue filling material and a preparation method thereof, wherein micronized decellularized bio-derived material is mixed with sustained-release microspheres containing drugs, mixed with a gel solution before use, and then injected into a recipient area. The material has the advantage of being able to be arbitrarily molded in the recipient area, but the invention does not involve technical contents such as the dispersion stability of the microparticles in the gel solution and the injection resistance.

[0017] Publication No. CN104055795A discloses an injectable implant and its preparation method, which is composed of amniotic membrane microparticles and sodium chloride phosphate physiological solution, which are prepared into a mixed suspension by a high-speed microfluidic device and sterilized by radiation. However, the invention does not solve the technical problems such as the uniformity and stability of the dispersion of the mixed microparticles, the smoothness of injection using a small diameter injection needle (minimally invasive injection), and the feasibility of sterilization.

[0018] Publication number CN113769168 A discloses a decellular matrix microparticle product for soft tissue filling and repair and a preparation method thereof, wherein the decellular matrix microparticle product for soft tissue filling and repair is composed of 2.0-10% decellular matrix microparticles, 0.1-5.0% suspending agent, and water for injection. The decellularized matrix is ​​composed of decellularized matrix microparticles with different degrees of cross-linking, and the suspending agent is selected from one or more of hyaluronic acid, carboxymethyl cellulose, hydroxypropyl methylcellulose, collagen, and gelatin. However, the invention does not solve the technical problems of uniformity and stability of microparticle dispersion after mixing, injection blockage using a small diameter injection needle (minimally invasive injection), and feasibility of sterilization after mixing.

[0019] The publication number CN 114949359 A discloses a decellular matrix microparticle implant and a preparation method thereof, wherein the decellular matrix microparticle implant comprises the following components: decellular matrix microparticles: 2.50%-60.00%; mixed gel phase 15.00%-75.00%; solvent: 7.50%-75.00%. The mixed gel phase comprises a cross-linked gel phase and a non-cross-linked gel phase, and the raw materials are selected from at least one of sodium hyaluronate, sodium polyglutamate, etc.; the solvent is selected from one of glycerol, physiological saline, and water for injection. The invention claims that the implant provided has excellent lubricity and injectability, and can be injected uniformly and continuously. However, the invention has the problem that the mixed gel phase has a high concentration and contains a cross-linked gel phase component, which easily causes uneven dispersion of the decellular matrix microparticles and leads to blockage of small diameter needle injection (poor minimally invasive injectability). At the same time, the invention has the problem that wet heat sterilization after mixing damages the decellular matrix structure.

[0020] Publication No. CN116531561 A discloses a dermal implant and a preparation method thereof, wherein the dermal implant is composed of microspheres and a filling liquid, wherein the microspheres are polylactic acid / hydroxyethyl cellulose microspheres, and the filling liquid includes a suspending dispersant and a buffer salt, and the dispersant is selected from at least one of hyaluronic acid, cellulose derivatives, and collagen, and is intended to provide a filler with a lasting filling effect. However, the invention does not solve the related technical problems such as the uniformity and stability of the dispersion of the particles after mixing, the minimally invasive injectability, and the feasibility of sterilization after mixing.

[0021] Publication No. CN111886031 A discloses a polycaprolactone microsphere filler containing collagen peptides and a preparation method thereof. The prepared polycaprolactone microspheres containing collagen peptides use a suspending agent consisting of a solute (at least one selected from the group consisting of carboxymethyl cellulose (CMC), hydroxypropyl methylcellulose (HPMC), hyaluronic acid, lidocaine, polydeoxyribonucleotides (PDRN), polynucleotides (PN) and mixtures thereof), a lubricant (glycerol), and an aqueous carrier (distilled water, saline or phosphate buffer). The suspending agent used does not solve the problem that the microspheres are easy to aggregate into agglomerates, and the suspending agent mentioned in the invention does not involve research on a specific formula, whether it has the ability to disperse microspheres, whether it has the ability to reduce injection force, etc.

[0022] Therefore, there is an urgent need in the art to develop a decellularized matrix microparticle implant that has good biocompatibility, natural biological components, structure and viscoelasticity, is not easily displaced after implantation, maintains for a long time, can induce endogenous regeneration, has a good repair effect, and can be minimally invasively injected (appropriate particle size, good dispersion uniformity, and dispersion stability), is easy to use clinically, and is suitable for large-scale production. [Summary of the invention]

[0023] In order to solve the above technical problems, the present invention provides an acellular matrix microparticle implant (hereinafter referred to as implant), which has good biocompatibility, natural biological components, structure and viscoelasticity, is not easy to shift after implantation, maintains for a long time, can induce endogenous regeneration, has good repair effect, and can be minimally invasively injected (appropriate particle size, good dispersion uniformity, and dispersion stability), is easy to use clinically, and is suitable for large-scale production.

[0024] First invention purpose: The injectable acellular matrix microparticle implant provided by the present invention consists of two parts: acellular matrix microparticles and a suspending agent, which are independently packaged, sterilized separately, and mixed before use.

[0025] Furthermore, the injectable acellular matrix microparticle implant provided by the present invention is composed of acellular matrix microparticles pre-packaged in a syringe and a suspending agent pre-packaged in a syringe or a glass bottle, which are independently packaged, sterilized separately, and mixed before use. After mixing, the microparticles do not aggregate or settle, are evenly and stably dispersed, have low fluidity, and can be smoothly passed through a small diameter needle (27G and 30G) for minimally invasive injection.

[0026] Furthermore, the mixing ratio is acellular matrix microparticles: suspending agent = 35 mg-200 mg: 1 ml.

[0027] Furthermore, the acellular matrix microparticles are prepared from pig small intestinal submucosa as raw material through the steps of inactivation, decellularization, freeze drying, granulation, packaging, sterilization and the like.

[0028] The decellularized matrix microparticles are obtained by screening using any two sieves within the range of a 40-mesh sieve (pore size 380 μm) and a 300-mesh sieve (pore size 48 μm).

[0029] The decellularized matrix particles are provided in the form of pre-sealed syringes, and the packaging is selected from syringes that match the sterilization method of the decellularized matrix particles, such as any one of cyclic olefin polymer (COP) syringes, cyclic olefin copolymer (COC) syringes, and borosilicate glass syringes suitable for radiation sterilization, such as polypropylene syringes suitable for ethylene oxide sterilization.

[0030] The decellularized matrix particles are provided in the form of pre-sealed syringes, and the sterilization method is selected to be suitable for the decellularized matrix and its packaging, such as radiation sterilization or ethylene oxide sterilization.

[0031] The acellular matrix particles are provided in the form of being pre-filled in a syringe, and the volume occupied by the particles in the syringe is at least greater than the volume of the suspending agent required when the particles are mixed with the suspending agent.

[0032] The suspending agent at least comprises glycerol, sodium hyaluronate, phosphate buffer and other components.

[0033] The concentration of glycerol in the suspending agent is 0.2%-1.0%.

[0034] The molecular weight of sodium hyaluronate in the suspending agent is in the range of 1 million to 1.6 million Daltons, and the concentration is 0.2% to 0.5%. Special note: The cohesive force of hyaluronic acid is the mutual attraction between adjacent parts of the same substance. This mutual attraction is the manifestation of the molecular force between molecules of the same substance, and here it specifically refers to the attraction of hydrogen bonds in hyaluronic acid.

[0035] Cohesion is an important property of hyaluronic acid, which directly affects the shaping effect of hyaluronic acid. Hyaluronic acid gels with higher cohesion can maintain a better shape, while gels with lower cohesion are easier to spread and may deform or even disperse under compression. This means that cohesion plays a key role in the shape and effect of hyaluronic acid after injection.

[0036] The viscosity, elasticity and cohesion of hyaluronic acid together determine its behavior and effect after injection. Highly viscous hyaluronic acid is not easy to shift and requires greater force to move and stretch it, so it will stay in its original position after injection. The more elastic the filler material, the better its resistance, which can better resist gravity and skin sagging, and provide a stronger lifting force for the upper covering tissue. When pressure, tension and twisting force are applied to the injection site, the highly elastic hyaluronic acid can return to its original shape.

[0037] Generally, the larger the molecular weight of hyaluronic acid, the greater its cohesive force.

[0038] The phosphate buffer in the suspending agent is composed of sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate and water, and plays a role in regulating pH and osmotic pressure.

[0039] The phosphate buffer in the suspending agent can adjust the pH of the suspending agent to 6.5-7.5 and the osmotic pressure to 270-350 mOsmol / L.

[0040] The suspending agent may be added with a local anesthetic, such as any one selected from lidocaine and procaine.

[0041] The suspending agent may be added with active substances, such as any one or a combination of amino acids, polypeptides, vitamins, and cytokines.

[0042] The suspending agent may be added with an anti-inflammatory agent, such as any one selected from steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, or a combination thereof.

[0043] The suspending agent may be added with an antiallergic agent, such as any one selected from diphenhydramine, promethazine, chlorpheniramine, calcium gluconate, and adrenal glucocorticoid, or a combination thereof.

[0044] The suspending agent is provided in the form of a pre-sealed syringe (bottle), and its packaging is selected from a container that matches the sterilization method of the suspending agent, such as any one of a cycloolefin polymer (COP) syringe (bottle), a cycloolefin copolymer (COC) syringe (bottle), a borosilicate glass syringe (bottle), and a polypropylene syringe (bottle).

[0045] The suspending agent pre-sealed in the syringe (bottle) is sterilized by moist heat sterilization.

[0046] The injectable acellular matrix microparticle implant provided by the present invention is prepared by mixing the acellular matrix microparticles with the suspending agent by means of a three-way pipe before use, and the mixing ratio is acellular matrix microparticles: suspending agent = 35mg-200mg: 1ml.

[0047] In the injectable acellular matrix microparticle implant provided by the present invention, during the mixing process of the acellular matrix microparticles and the suspending agent, the suspending agent should be first pushed toward the microparticles and then pushed back, and the pushing should be repeated at least 50 times.

[0048] The second purpose of the present invention is to provide an injectable acellular matrix microparticle implant for use in cosmetic surgery, oral dental surgery, and cartilage defect repair.

[0049] The cosmetic and plastic surgery uses include, on the one hand, injection into the deep dermis to subcutaneous for the repair of wrinkles (such as nasolabial furrows) and various skin surface depressions, to achieve the purpose of lasting and natural cosmetic effects after micro-filling and micro-plastic surgery; on the other hand, injection into the superficial to middle layers of the skin for the repair of fine lines around the corners of the eyes, forehead, back of the hands, and neck, to achieve the purpose of removing fine lines and brightening the skin tone; yet another aspect includes injection into deep tissues such as the fascia layer, to restore the facial contour to a firm state, provide bony support, and shape a three-dimensional bone structure (such as rhinoplasty).

[0050] The oral tooth plastic surgery purpose is to inject into the local gums to reduce the gingival wedge-shaped gap and improve the black triangle of the gingival papilla to achieve the oral tooth plastic surgery beauty purpose.

[0051] The cartilage defect repair purpose is to inject into the local cartilage defect to repair and regenerate the damaged cartilage caused by strain or aging.

[0052] The above-mentioned use of the implant is carried out by minimally invasive injection, that is, injection is carried out through a small diameter needle (27G and 30G).

[0053] The third object of the present invention is to provide a method for preparing an injectable acellular matrix microparticle implant product, comprising the following steps: Step 1, preparation of acellular matrix microparticles

[0054] The preparation method of the acellular matrix microparticles of the present invention is to use porcine small intestinal submucosa as raw material, and to obtain the acellular matrix microparticles through the steps of inactivation, decellularization, freeze drying, granulation, packaging, sterilization, etc. The specific steps are as follows:

[0055] (1) Inactivation: The submucosa of the small intestine of pigs was inactivated by treating it with a mixed aqueous solution of 0.5%-1.5% peracetic acid and 15%-25% ethanol under ultrasonic conditions at room temperature for 30-120 min.

[0056] This step can reduce the microbial load of SIS by inactivating the submucosa of the pig small intestine and inactivate a variety of possible viruses.

[0057] (2) Decellularization: The inactivated SIS was first washed with water for 3 times under ultrasonic conditions, packaged into small packages, quickly frozen overnight, thawed the next day, and the freeze-thaw steps of "washing 3 times - packaging - freezing - thawing" were repeated for at least 2-4 cycles; a mixed aqueous solution containing 0.01%-0.05% trypsin and 0.01%-0.05% EDTA was used to treat at 36±2°C for 15-60 min under ultrasonic conditions, and then washed with PBS for 3 times; in a 1.5% sodium chloride hypertonic solution, it was treated at 36±2°C for 15-60 min under ultrasonic conditions, and then washed with water for 5 times; in a 10mM-40mM NaOH aqueous solution, it was treated at 36±2°C for 15-120 min under ultrasonic conditions; then, it was washed with water under ultrasonic conditions until neutral.

[0058] This step adopts a mild decellularization process, which combines physical, chemical and biological decellularization methods to fully remove the immunogenic components in SIS while retaining the natural three-dimensional structure and active ingredients of SIS to the greatest extent, including collagen, fibronectin, glycosaminoglycans and various growth factors.

[0059] (3) Freeze-drying: Fix the decellularized SIS sheet on a mold and freeze-dry it.

[0060] The freeze-drying process in this step allows the SIS active ingredients, such as fibronectin, laminin, glycosaminoglycans and various growth factors, to be stably combined with collagen. After implantation into the body, they are gradually released as the material degrades, thus helping the regeneration and deposition of the body's own ECM.

[0061] (4) Granulation: The freeze-dried SIS sheet is cut into pieces, frozen in liquid nitrogen and then crushed, and sieved using stainless steel sieves of different mesh sizes to obtain decellularized matrix microparticles; the obtained decellularized matrix microparticles are obtained by sieving using any two sieves within the range of a 40-mesh sieve (pore size 380 μm) and a 300-mesh sieve (pore size 48 μm).

[0062] The prepared microparticles can pass through an injection needle with an inner diameter smaller than that of the microparticles, such as a 27G needle (inner diameter 0.21 mm) and a 30G needle (inner diameter 0.16 mm). This is because the acellular matrix microparticles prepared in the present invention become soft and viscoelastic after being wetted by the suspending agent and can be deformed to pass through the needle.

[0063] (5) Packaging: The decellularized matrix microparticles are packed into syringes. The volume occupied by the microparticles in the syringe is at least larger than the volume of the suspending agent required for mixing with the suspending agent. The syringe is sealed with a stopper.

[0064] The prepared decellularized matrix microparticles are packaged in a syringe after weighing. They do not need to be weighed before use, and are directly mixed with a corresponding proportion of suspending agents through aseptic operation. The packaging is selected from a syringe that matches the sterilization method of the decellularized matrix microparticles, such as any one of a cycloolefin polymer (COP) syringe, a cycloolefin copolymer (COC) syringe, and a borosilicate glass syringe suitable for radiation sterilization, such as a polypropylene syringe suitable for ethylene oxide sterilization. The volume occupied by the microparticles in the syringe is at least greater than the volume of the suspending agent required when mixed with the suspending agent, in order to avoid the suspending agent from squeezing the microparticles during mixing and to help disperse and mix.

[0065] (6) Sterilization: The decellularized matrix particles pre-sealed in the syringe are sterilized by selecting a sterilization method suitable for the decellularized matrix and its packaging, such as cobalt 60 or electron beam radiation sterilization, or ethylene oxide sterilization.

[0066] The sterilization method selected for the decellularized matrix particles causes minimal damage to the original structure and viscoelasticity of the ECM.

[0067] Step 2, preparation of suspending agent

[0068] Prepare a suspending agent containing at least glycerol, sodium hyaluronate, phosphate buffer and other ingredients, dispense into syringes (bottles), add stoppers, and sterilize.

[0069] The concentration of the glycerol component in the suspending agent prepared in this step is 0.2%-1.0%.

[0070] The sodium hyaluronate component in the suspending agent prepared in this step has a molecular weight in the range of 1-1.6 million Daltons and a concentration of 0.2%-0.5%.

[0071] The phosphate buffer of the suspending agent prepared in this step is composed of sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate and water, and plays a role in maintaining the pH and osmotic pressure of the suspending agent within the physiological range.

[0072] The suspending agent prepared in this step has a pH of 6.5-7.5 and an osmotic pressure of 270-350 mOsmol / L.

[0073] The suspending agent prepared in this step may be added with a local anesthetic, such as any one selected from lidocaine and procaine.

[0074] The suspending agent prepared in this step may be added with active substances, such as any one or a combination of amino acids, polypeptides, vitamins, and cytokines.

[0075] The suspending agent prepared in this step may be added with an anti-inflammatory agent, such as any one or a combination of steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents.

[0076] The suspending agent prepared in this step may be added with an antiallergic agent, such as any one or a combination thereof selected from diphenhydramine, promethazine, chlorpheniramine, calcium gluconate, and adrenal glucocorticoid.

[0077] The suspending agent prepared in this step is packaged in a container that matches the sterilization method of the suspending agent, such as any one of a cycloolefin polymer (COP) syringe (bottle), a cycloolefin copolymer (COC) syringe (bottle), a borosilicate glass syringe (bottle), and a polypropylene syringe (bottle), and is sealed with a stopper.

[0078] The suspending agent prepared in this step is sterilized by moist heat sterilization.

[0079] Step 3: Mix

[0080] Before use, the decellularized matrix microparticles and the suspending agent are mixed with a three-way tube at a ratio of decellularized matrix microparticles: suspending agent = 35mg-200mg: 1ml. When mixing, the suspending agent should be pushed toward the microparticles first, then pushed back, and pushed repeatedly at least 50 times. The injectable decellularized matrix microparticle implant prepared after mixing has viscoelasticity similar to that of natural soft tissue, and is beneficial to cell diffusion, growth, proliferation, migration, differentiation and tissue remodeling after injection into the body; it has good plasticity and is not easy to shift after injection into the body.

[0081] After the acellular matrix implant composition provided by the present invention is implanted subcutaneously in rats, it can stimulate the regeneration of autologous collagen fibers, and the regenerated tissue is similar to the original autologous tissue, and the effect lasts for at least 24 weeks.

[0082] After mixing, the particles do not aggregate or settle, are evenly and stably dispersed, have low fluidity, and can pass smoothly through small diameter needles (27G and 30G).

[0083] Compared with the prior art, the present invention has the following beneficial effects:

[0084] (1) The injectable acellular matrix microparticle implant provided by the present invention has the advantages that the acellular matrix microparticles and the suspending agent are independently packaged and sterilized separately, and the selected sterilization method is appropriate, so that the natural ECM components, structure and viscoelasticity of the acellular matrix microparticles are completely preserved, so that the components in the suspending agent are not destroyed, which is conducive to the safe and effective endogenous induced regeneration after implantation in the body.

[0085] (2) The injectable acellular matrix microparticle implant provided by the present invention has the advantage that the problem of uniform dispersion of the acellular matrix microparticles in the suspension is solved by adding glycerol. The glycerol molecule contains three hydroxyl groups and a large hydrophobic group, which can form colloidal particles in water, which is conducive to the uniform dispersion of the microparticles in the suspending agent.

[0086] (3) The injectable acellular matrix microparticle implant provided by the present invention has the advantage that, by controlling the amount of glycerol added and adding the cohesive agent sodium hyaluronate, the problem of high suspension fluidity and displacement after implantation in the body is solved. Glycerol can disperse the acellular matrix microparticles. The higher the glycerol concentration, the more fully the microparticles are dispersed, but the greater the suspension fluidity, the greater the risk of displacement after implantation in the body, and the greater the impact on the osmotic pressure of the suspending agent. Therefore, it is more appropriate to control the glycerol concentration to a lower level that can fully disperse the microparticles. At the same time, by adding an appropriate amount of cohesive agent, the dispersion and cohesive effects can be better. The glycerol concentration added in the present invention is low, in the range of 0.2%-1.0%, and sodium hyaluronate with cohesiveness is also added. The cohesiveness (cohesiveness refers to the ability of the product to adhere or aggregate to each other) characteristics of the added sodium hyaluronate can make the suspension maintain the tendency of cohesive contraction, always try to maintain a spherical shape, not easy to flow, and not easy to shift after implantation in the body.

[0087] (4) The injectable acellular matrix microparticle implant provided by the present invention has the advantage that, by adding a stabilizer, sodium hyaluronate, the dispersion stability problem of the acellular matrix microparticle suspension after mixing and before use is solved.

[0088] Since the acellular matrix implant is not necessarily injected immediately after mixing, and is generally injected within 2 hours, it should be ensured that the suspension is dispersed and stable from mixing to use. The formula related to the stability of particles in the suspension is the Stokes formula:

[0089] V==2gd2(ρ0-ρ1) / 9η; in this formula, V (velocity) is the sinking or floating speed of the particle, g is the gravitational acceleration, d is the particle diameter, ρ0 is the particle density, ρ1 is the medium density, and η is the medium viscosity.

[0090] According to Stokes' formula, in order to reduce the sinking or floating speed of particles and improve the stability of the suspension, the adjustments that can be made are to reduce the d value, or reduce the ρ0-ρ1 value, or increase the η value.

[0091] It is difficult to effectively reduce the ρ0-ρ1 value, but the particle d value is determined, so increasing the medium viscosity η becomes the main means to improve the stability of the suspension. The present invention increases the viscosity by adding sodium hyaluronate to improve the dispersion stability of the suspension.

[0092] The added sodium hyaluronate has cohesiveness and dispersion stability on the one hand, and thickening properties on the other hand. Under the premise that the molecular weight of sodium hyaluronate is determined, if the concentration of sodium hyaluronate is too small, the cohesive effect and dispersion stability cannot be achieved. If it is too large, the viscosity is too high and the dispersion uniformity is affected. Therefore, the concentration of sodium hyaluronate added should be controlled within an appropriate range.

[0093] (5) The injectable acellular matrix microparticle implant provided by the present invention has the advantages that the concentration of glycerol in the suspending agent is 0.2%-1.0%, and the concentration of sodium hyaluronate with a molecular weight of 1 million-1.6 million is 0.2%-0.5%, so that the dispersion uniformity, dispersion stability and cohesion of the suspension reach an optimal balance state, solve the problem of aggregation and sedimentation of microparticles in the suspension, and solve the problem of high fluidity and easy displacement of the suspension, so that the implant can be minimally invasively injected, can smoothly pass through a small diameter needle (27G, 30G), has a small pushing force, an average pushing force of less than 10N, and a maximum pushing force of less than 30N.

[0094] (6) The injectable decellular matrix microparticle implant provided by the present invention has the advantages that the decellular matrix microparticles are dry sterilized, which will not cause collagen cross-linking and glycosaminoglycan degradation. After mixing with the suspending agent, they have suitable viscoelasticity, and the loss or viscosity modulus at 1Hz is 10% to 20% of the storage or elastic modulus, which is consistent with the viscoelasticity of natural soft tissue. This property makes the material conducive to cell diffusion, growth, proliferation, migration, differentiation and tissue remodeling after implantation in the body. At the same time, the viscoelasticity can enable the microparticles to smoothly pass through injection needles with an inner diameter smaller than that of the microparticles, such as 27G (inner diameter 0.21mm) and 30G (inner diameter 0.16mm) injection needles, which has the advantages of minimally invasive injection, retaining larger microparticles and delaying the degradation rate.

[0095] (7) The decellularized matrix microparticles prepared by the decellularization technology of the present invention have the advantages of being able to fully remove the immunogenic components in SIS and having good biocompatibility, while being able to retain the natural three-dimensional structure of SIS and the active ingredients, including collagen, fibronectin, laminin, glycosaminoglycans and various growth factors, to the greatest extent. They have good hydrophilicity and water absorption properties, and their weight after water absorption can reach 6-10 times that before water absorption, thus providing immediate volume filling for the implantation site.

[0096] (8) After the acellular matrix implant prepared by the present invention is subcutaneously implanted in rats, no redness, swelling, bleeding, or ulceration occurs at the implantation site, and the tissue inflammatory response is relatively mild. The implantation site does not shift, and new autologous collagen fibers can be induced to grow in, and the autologous ECM tissue can be regenerated and deposited at the implantation site, thereby maintaining a long-term tissue repair effect.

[0097] (9) The preparation method of the acellular matrix microparticle implant of the present invention has a simple preparation process and is suitable for large-scale production. It is a terminally sterilized product with no microbial load and good safety.

Brief Description of the Drawings

[0098] Figure 1 Photograph of the acellular matrix implant composition prepared according to the present invention (Example 1).

[0099] Figure 2 and Figure 3 These are scanning electron microscope photos of the decellularized matrix microparticles prepared in the present invention (Example 1); X500 times and X30,000 times. Figure 4 Viscoelasticity test graph of the acellular matrix implant prepared in the present invention (Example 1).

[0100] Figure 5 and Figure 6 These are photos of suspensions prepared according to the present invention (Example 1) and Comparative Example 3.

[0101] Figure 7 and Figure 8 It is a test chart of the pushing force of the suspension prepared in the present invention (Example 1) and Comparative Example 3 through a 27G needle. Fig. 9 and Fig.10 It is the photograph of the suspension prepared by the present invention (Example 1) and Comparative Example 2.

[0102] Fig.11 and Fig.12 It is a photograph of the suspension prepared in the present invention (Example 1) and Comparative Example 2 after being left to stand for 4 hours.

[0103] Fig.13 , 14 and Fig.15 This is the particle distribution diagram of the front section, middle section and back section of the extrudate after the suspension prepared in the present invention (Example 1) was left to stand for 4 hours.

[0104] Fig.16 The diagram is a tissue section at different time points after the acellular matrix implant composition prepared in the present invention (Example 1) is implanted subcutaneously in rats.

[0105] As used herein, the term "comprising" (and related terms such as "including" or "having" or "including") includes those embodiments, such as any composition of matter, method or process "consists of" or "consists essentially of" the described features.

[0106] The applicant needs to explain that in this patent, when referring to numbers or numerical ranges, the use of data terms means that the numbers or numerical ranges referred to may have experimental changes or variability ranges or statistical experimental errors, and the point values ​​of the data may also be regarded as approximate values, that is, the numbers or numerical ranges may vary, and the variation is usually -10% to +10% of the numbers or numerical ranges;

[0107] Beneficial or advantageous values ​​are preferably positive 0% to +10%; harmful or unfavorable values ​​are preferably negative, i.e. 0% to -10%; in addition, the values ​​in the test results, unless otherwise specified, are usually the average of the test results of at least three samples or examples.

[0108] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any method, equipment, and material of the prior art similar to or equivalent to the methods, equipment, and materials in the embodiments of the present invention can also be used to realize the present invention.

[0109] The following is an explanation of the embodiments of the present invention by specific examples. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0110] Before describing the specific embodiments of the present invention, it should be understood that the protection scope of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the embodiments of the present invention are for describing the specific embodiments rather than for limiting the protection scope of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms. [Specific implementation method]

[0111] The present invention will be further explained and illustrated below in conjunction with specific embodiments.

[0112] Example 1

[0113] Step 1. Preparation of acellular matrix microparticles

[0114] (1) Inactivation: The submucosa of the small intestine of pigs was inactivated by soaking in a mixed aqueous solution of 1% peracetic acid and 20% ethanol under ultrasonic conditions at room temperature for 60 minutes.

[0115] (2) Decellularization: The inactivated SIS was first washed three times with water under ultrasonic conditions, packaged into small packages, quickly frozen overnight, thawed the next day, and the freeze-thaw steps of "wash three times - package - freeze - thaw" were repeated for three cycles; a mixed aqueous solution containing 0.05% trypsin and 0.02% EDTA was used to treat at 36±2°C for 30 min under ultrasonic conditions, and then washed three times with PBS; in a 1.5% sodium chloride hypertonic solution, it was treated at 36±2°C for 30 min under ultrasonic conditions, and then washed five times with water; in a 25 mM NaOH aqueous solution, it was treated at 36±2°C for 30 min under ultrasonic conditions; and then washed with water ultrasonically until neutral.

[0116] (3) Freeze-drying: Stack 4 layers of SIS sheets, fix them on a mold, and dry them.

[0117] (4) Granulation: The freeze-dried SIS was cut into small pieces, frozen with liquid nitrogen and then crushed, and sieved using a 40-mesh sieve (pore size 380 μm) and a 300-mesh sieve (pore size 48 μm).

[0118] (5) Packaging: Weigh the decellularized matrix microparticles and dispense 80 mg into a COP syringe. The volume of the microparticles in the syringe should be larger than 1 ml of the suspending agent required for mixing with the suspending agent. Then, seal the syringe with a stopper.

[0119] (6) Sterilization: Select cobalt 60 sterilization method with a radiation dose of 25kGy-30kGy.

[0120] Step 2: Preparation of suspending agent

[0121] Use phosphate buffer to prepare the suspending agent, the glycerol concentration in the suspending agent is 0.5%, and the sodium hyaluronate concentration is 0.2%. After stirring evenly and fully dissolving, dispense into glass syringes, each syringe has a dispensing volume of 1 ml, add a stopper, and sterilize using a wet sterilization method at 121°C for 30 minutes.

[0122] Step 3: Mix

[0123] Before use, the decellularized matrix microparticles and the suspending agent were mixed with a three-way tube at a ratio of decellularized matrix microparticles: suspending agent = 80 mg: 1 ml. When mixing, the suspending agent was first pushed toward the microparticles, then pushed back, and repeated 200 times.

[0124] The acellular matrix microparticle implant prepared according to this embodiment can be minimally invasively injected into the deep layer of the dermis to the subcutaneous layer, and is used to repair wrinkles (such as nasolabial furrows) and various skin surface depressions, achieving the purpose of long-lasting and natural cosmetic effects after micro-filling and micro-plastic surgery.

[0125] Example 2

[0126] Step 1. Preparation of acellular matrix microparticles

[0127] (1) Inactivation: The submucosa of the small intestine of pigs was inactivated by soaking in a mixed aqueous solution of 0.5% peracetic acid and 25% ethanol under ultrasonic conditions at room temperature for 120 min.

[0128] (2) Decellularization: The inactivated SIS was first washed three times with water under ultrasonic conditions, packaged into small packages, quickly frozen overnight, thawed the next day, and the freeze-thaw steps of "wash three times - package - freeze - thaw" were repeated for 4 cycles; a mixed aqueous solution containing 0.1% trypsin and 0.05% EDTA was used to treat at 36±2°C for 30 min under ultrasonic conditions, and then washed three times with PBS; in a 1.5% sodium chloride hypertonic solution, it was treated at 36±2°C for 15 min under ultrasonic conditions, and then washed five times with water; in a 10 mM NaOH aqueous solution, it was treated at 36±2°C for 120 min under ultrasonic conditions; and then washed with water ultrasonically until neutral.

[0129] (3) Freeze-drying: Stack 4 layers of SIS sheets, fix them on a mold, and freeze-dry them.

[0130] (4) Granulation: The freeze-dried SIS was cut into small pieces, frozen in liquid nitrogen and then crushed, and sieved using an 80-mesh sieve (pore size 180 μm) and a 300-mesh sieve (pore size 48 μm).

[0131] (5) Packaging: Weigh the decellularized matrix microparticles and dispense 35 mg into a COP syringe. The volume of the microparticles in the syringe should be larger than 1 ml of the suspending agent required for mixing with the suspending agent. Then, seal the syringe with a stopper.

[0132] (6) Sterilization: Select cobalt 60 sterilization method with a radiation dose of 25kGy-30kGy.

[0133] Step 2: Preparation of suspending agent

[0134] Use phosphate buffer to prepare the suspending agent, the glycerol concentration in the suspending agent is 0.2%, and the sodium hyaluronate concentration is 0.5%. Stir and dissolve evenly to obtain the suspending agent, which is then dispensed into glass syringes with a dispensing volume of 1 ml per syringe. Stopper the syringes and sterilize them using a wet sterilization method at 121°C for 30 minutes.

[0135] Step 3: Mix

[0136] Before use, the decellularized matrix microparticles and the suspending agent were mixed with a three-way tube at a ratio of decellularized matrix microparticles: suspending agent = 60 mg: 1 ml. When mixing, the suspending agent was first pushed toward the microparticles, then pushed back, and repeated 200 times.

[0137] The acellular matrix particles prepared in this embodiment are relatively small, and the particle concentration is low after being prepared with the suspending agent, which is suitable for minimally invasive injection into the superficial to middle layers of the skin, and is used to repair fine lines around the corners of the eyes, forehead, back of the hands, and neck, to achieve the purpose of removing fine lines and brightening the skin tone.

[0138] Example 3

[0139] Step 1. Preparation of acellular matrix microparticles

[0140] (1) Inactivation: The submucosa of the small intestine of pigs was inactivated by soaking in a mixed aqueous solution of 1.5% peracetic acid and 25% ethanol under ultrasonic conditions at room temperature for 30 minutes.

[0141] (2) Decellularization: The inactivated SIS was first washed three times with water under ultrasonic conditions, packaged into small packages, quickly frozen overnight, thawed the next day, and the freeze-thaw steps of "wash three times - package - freeze - thaw" were repeated for 2 cycles; a mixed aqueous solution containing 0.01% trypsin and 0.01% EDTA was used to treat at 36±2°C for 60 min under ultrasonic conditions, and then washed three times with PBS; in a 1.5% sodium chloride hypertonic solution, it was treated at 36±2°C for 40 min under ultrasonic conditions, and then washed five times with water; in a 40 mM NaOH aqueous solution, it was treated at 36±2°C for 15 min under ultrasonic conditions; and then washed with water ultrasonically until neutral.

[0142] (3) Freeze-drying: Stack 4 layers of SIS sheets, fix them on a mold, and freeze-dry them.

[0143] (4) Granulation: The freeze-dried SIS was cut into small pieces, frozen with liquid nitrogen and then crushed, and sieved using a 40-mesh sieve (pore size 380 μm) and a 90-mesh sieve (pore size 160 μm).

[0144] (5) Packaging: Weigh the decellularized matrix microparticles and dispense 200 mg into a COP syringe. The volume of the microparticles in the syringe should be larger than 1 ml of the suspending agent required for mixing with the suspending agent. Then, seal the syringe with a stopper.

[0145] (6) Sterilization: Select cobalt 60 sterilization method with a radiation dose of 25kGy-30kGy.

[0146] Step 2: Preparation of suspending agent

[0147] Use phosphate buffer to prepare the suspending agent, the glycerol concentration in the suspending agent is 1%, and the sodium hyaluronate concentration is 0.2%. After stirring evenly and fully dissolving, dispense into glass syringes, each syringe has a dispensing volume of 1 ml, add a stopper, and sterilize using a wet sterilization method at 121°C for 30 minutes.

[0148] Step 3: Mix

[0149] Before use, the decellularized matrix microparticles and the suspending agent were mixed with a three-way tube in a ratio of decellularized matrix microparticles: suspending agent = 200 mg: 1 ml. During mixing, the suspending agent was first pushed toward the microparticles, then pushed back, and the pushing was repeated 200 times. Then, related tests were performed with other embodiments.

[0150] The acellular matrix particles prepared in this embodiment are relatively large, and the particle concentration is relatively high after mixing with the suspending agent, which is suitable for minimally invasive injection into deep tissues such as the fascia layer, so as to achieve the purpose of restoring and tightening the facial contour, providing bony support, and shaping three-dimensional bone phases (such as rhinoplasty).

[0151] Example 4

[0152] The purpose of setting this example is to explore the influence of glycerol on the dispersion uniformity, dispersion stability and fluidity of the suspension.

[0153] In addition to being related to the suspending agent components, the dispersion uniformity of the suspension is also related to the size and number of the acellular matrix particles. The smaller the size and the greater the number, the more difficult it is to mix. Since the size range of the acellular matrix particles of the present invention has been determined, this experiment selected the condition with the largest number of particles, that is, particles: suspending agent = 200 mg: 1 ml, to verify the effect of the glycerol component in the suspending agent on the dispersion uniformity.

[0154] The difference between this embodiment and embodiment 1 is that the mixture is mixed in the ratio of acellular matrix particles: suspending agent = 200 mg: 1 ml; the suspending agent does not contain sodium hyaluronate, and the mixture is divided into 6 groups according to different concentrations of glycerol added.

[0155] The following experiments were conducted in this example: observing the aggregation of particles after mixing; immediately extruding through a 27G needle after mixing, observing the extrusion difficulty, needle clogging, and suspension flow; after mixing, the syringe was left standing for 4 hours to observe the precipitation and precipitation of the suspension, and then extruding through a 27G needle to observe the extrusion difficulty, needle clogging, and suspension flow. The experimental results are shown in Table 1.

[0156] Table 1 Observation results of dispersion uniformity, dispersion stability and fluidity of each group of samples in Example 4

[0157]

[0158] According to Table 1, it can be seen that: (1) When the suspending agent is composed of phosphate buffer only, does not contain sodium hyaluronate, does not contain glycerol or has a low glycerol concentration (concentration 0.1%), the suspension has poor dispersion uniformity, but acceptable dispersion stability and fluidity; (2) As the glycerol concentration of the suspending agent increases, the dispersion uniformity of the suspension improves, but the dispersion stability becomes worse and the fluidity increases. Note: If the dispersion uniformity of the suspension is to be solved, it can be solved by adding a certain amount of dispersant glycerol, but the other side of the added glycerol is that the dispersion stability and fluidity may be unacceptable, so it should be considered to add a dispersion stabilizer and / or a cohesive agent to the suspending agent.

[0159] Example 5

[0160] The purpose of setting this example is to explore the effect of 0.1% sodium hyaluronate on the dispersion stability and fluidity of the suspension.

[0161] In addition to being related to the suspending agent component, the dispersion stability of the suspension is also related to the size and quantity of the decellularized matrix particles. For example, the fewer the number of particles in the suspension, the less mutual support between the particles, the more likely it is to be unstable, and the greater the fluidity. Since the size range of the decellularized matrix particles of the present invention has been determined, this experiment selects the condition with the least particle content, the worst stability, and the greatest fluidity, that is, the particles: suspending agent = 35 mg: 1 ml.

[0162] The difference between this embodiment and embodiment 1 is that the mixture is mixed in the ratio of acellular matrix microparticles: suspending agent = 35 mg: 1 ml; the suspending agent contains 0.1% sodium hyaluronate, and is divided into 6 groups according to different concentrations of glycerol added.

[0163] The following experiments were conducted in this example: observing the aggregation of particles after mixing; immediately extruding through a 27G needle after mixing, observing the extrusion difficulty, needle clogging, and suspension flow; after mixing, the syringe was left standing for 4 hours to observe the precipitation and precipitation of the suspension, and then extruding through a 27G needle to observe the extrusion difficulty, needle clogging, and suspension flow. The experimental results are shown in Table 2.

[0164] Table 2 Observation results of dispersion uniformity, dispersion stability and fluidity of each group of samples in Example 5

[0165]

[0166] According to Table 2, it can be seen that: when the concentration of sodium hyaluronate is 0.1%, the dispersion stability of the suspension can be improved to a certain extent, and it can resist the sedimentation force of low concentration glycerol (concentration equal to or less than 0.2%), but it is still not enough to resist the sedimentation force of particles in high concentration glycerol (concentration equal to or greater than 1.0%); when the concentration of sodium hyaluronate is 0.1%, the suspension has high fluidity and no obvious cohesion.

[0167] Example 6

[0168] The purpose of setting this example is to explore the effect of 0.2% sodium hyaluronate on the dispersion stability and fluidity of the suspension.

[0169] In addition to being related to the suspending agent component, the dispersion stability of the suspension is also related to the size and quantity of the decellularized matrix particles. For example, the fewer the number of particles in the suspension, the less mutual support between the particles, the more likely it is to be unstable, and the greater the fluidity. Since the size range of the decellularized matrix particles of the present invention has been determined, this experiment selects the condition with the least particle content, the worst stability, and the greatest fluidity, that is, the particles: suspending agent = 35 mg: 1 ml.

[0170] The difference between this embodiment and embodiment 1 is that the mixture is mixed in the ratio of acellular matrix microparticles: suspending agent = 35 mg: 1 ml; the suspending agent contains 0.2% sodium hyaluronate, and is divided into 6 groups according to different concentrations of glycerol added.

[0171] The following experiments were conducted in this embodiment: observing the aggregation of particles after mixing; immediately extruding through a 27G needle after mixing, observing the extrusion difficulty, needle clogging, and suspension flow; after mixing, the syringe was left standing for 4 hours to observe the precipitation and precipitation of the suspension, and then extruding through a 27G needle to observe the extrusion difficulty, needle clogging, and suspension flow. The experimental results are shown in Table 3.

[0172] Table 3 Observation results of dispersion uniformity and dispersion stability of each group of samples in Example 6

[0173]

[0174]

[0175] According to Table 3, it can be seen that when the sodium hyaluronate concentration is 0.2% and the glycerol concentration is 0.2%-1.0%, the dispersion uniformity, dispersion stability and fluidity of the suspension are all very good and acceptable; but it is still not enough to resist the sedimentation force and fluidity of high concentration glycerol (concentration is 1.5%).

[0176] Example 7 The purpose of this example is to explore the effect of 0.5% sodium hyaluronate on the dispersion stability and fluidity of the suspension.

[0177] In addition to being related to the suspending agent component, the dispersion stability of the suspension is also related to the size and quantity of the decellularized matrix particles. For example, the fewer the number of particles in the suspension, the less mutual support between the particles, the more likely it is to be unstable, and the greater the fluidity. Since the size range of the decellularized matrix particles of the present invention has been determined, this experiment selects the condition with the least particle content, the worst stability, and the greatest fluidity, that is, the particles: suspending agent = 35 mg: 1 ml.

[0178] The difference between this embodiment and embodiment 1 is that the mixture is mixed in the ratio of decellularized matrix particles: suspending agent = 35 mg: 1 ml; the suspending agent contains 0.5% sodium hyaluronate, and is divided into 6 groups according to different concentrations of glycerol added.

[0179] The following experiments were conducted in this embodiment: observing the aggregation of particles after mixing; immediately extruding through a 27G needle after mixing, observing the extrusion difficulty, needle clogging, and suspension flow; after mixing, the syringe was left standing for 4 hours to observe the precipitation and precipitation of the suspension, and then extruding through a 27G needle to observe the extrusion difficulty, needle clogging, and suspension flow. The experimental results are shown in Table 4.

[0180] Table 4 Observation results of dispersion uniformity and dispersion stability of each group of samples in Example 7

[0181]

[0182]

[0183] According to Table 4, it can be seen that when the sodium hyaluronate concentration is 0.5% and the glycerol concentration is 0.2%-1.0%, the dispersion uniformity, dispersion stability and fluidity of the suspension are very good; when the sodium hyaluronate concentration is 0.5% and the glycerol concentration is 1.5%, the viscosity of sodium hyaluronate is still not enough to resist the sedimentation force of 1.5% glycerol.

[0184] Example 8 The purpose of this example is to explore the effect of 0.8% sodium hyaluronate on the dispersion stability and fluidity of the suspension.

[0185] In addition to being related to the suspending agent component, the dispersion stability of the suspension is also related to the size and quantity of the decellularized matrix particles. For example, the fewer the number of particles in the suspension, the less mutual support between the particles, the more likely it is to be unstable, and the greater the fluidity. Since the size range of the decellularized matrix particles of the present invention has been determined, this experiment selects the condition with the least particle content, the worst stability, and the greatest fluidity, that is, the particles: suspending agent = 35 mg: 1 ml.

[0186] The difference between this embodiment and embodiment 1 is that the mixture is mixed in the ratio of decellularized matrix particles: suspending agent = 35 mg: 1 ml; the suspending agent contains 0.8% sodium hyaluronate, and is divided into 6 groups according to different concentrations of glycerol added.

[0187] The following experiments were conducted in this example: observing the aggregation of particles after mixing; immediately extruding through a 27G needle after mixing, observing the extrusion difficulty, needle clogging, and suspension flow; standing the syringe upright for 4 hours after mixing, observing the precipitation and precipitation of the suspension, and extruding through a 27G needle, observing the extrusion difficulty, needle clogging, and suspension flow. The experimental results are shown in Table 5.

[0188] Table 5 Observation results of dispersion uniformity and dispersion stability of each group of samples in Example 8

[0189]

[0190] According to Table 5, it can be seen that when the sodium hyaluronate concentration is 0.8%, the suspension has good dispersion stability and low fluidity, but due to excessive viscosity, the suspension has particle aggregation and clogging of the needle.

[0191] Example 9

[0192] The purpose of setting up this comparative example: Based on the results of the exploration of the above Examples 4-8, further confirm the influence of 0.2%-0.5% sodium hyaluronate and 0.2%-1.0% glycerol in the suspending agent on the dispersion uniformity, dispersion stability and fluidity of suspensions with different particle contents.

[0193] The difference between this embodiment and embodiment 1 is that the decellularized matrix particles: suspending agent are mixed in two ratios of 35 mg: 1 ml and 200 mg: 1 ml, and cross-experiments are conducted with the lowest and highest values ​​of 0.2%-0.5% sodium hyaluronate and 0.2%-1.0% glycerol in the suspending agent, respectively, and divided into 8 groups.

[0194] The following experiments were conducted in this example: observing the aggregation of particles after mixing; immediately extruding through a 27G needle after mixing, observing the extrusion difficulty, needle clogging, and suspension flow; after mixing, the syringe was left standing for 4 hours to observe the precipitation and precipitation of the suspension, and extruding through a 27G needle to observe the extrusion difficulty, needle clogging, and suspension flow. The experimental results are shown in Table 6.

[0195] Table 6 Observation results of dispersion uniformity and dispersion stability of each group of samples in Example 9

[0196]

[0197] According to Table 6, it is found that when the concentration of glycerol in the suspending agent is 0.2-1.0%, the concentration of sodium hyaluronate is 0.2-0.5%, and the mixing ratio of acellular matrix microparticles: suspending agent = 35mg-200mg: 1ml, the dispersion uniformity, dispersion stability and cohesion of the suspension are in an optimal balance state. The advantages of the present invention are further highlighted by Comparative Examples 1 to 6.

[0198] Comparative Example 1 This comparative example is different from Example 1 in that the decellularized matrix microparticles and the suspending agent in Example 1 are packaged independently and sterilized separately, while the decellularized matrix microparticles and the suspending agent in this comparative example are mixed and packaged in syringes before being sterilized by Cobalt 60 radiation.

[0199] The difference between Comparative Example 2 and Example 1 is that the suspending agent does not contain sodium hyaluronate.

[0200] The difference between Comparative Example 3 and Example 1 is that the suspending agent does not contain glycerol.

[0201] The difference between Comparative Example 4 and Example 1 is that the concentration of sodium hyaluronate in the suspending agent is 0.1% and the concentration of glycerol is 1.5%.

[0202] The difference between Comparative Example 5 and Example 1 is that the concentration of sodium hyaluronate in the suspending agent is 0.8% and the concentration of glycerol is 0.1%.

[0203] The difference between Comparative Example 6 and Example 1 is that the mixing ratio of the decellularized matrix microparticles and the suspending agent is 250 mg: 1 ml.

[0204] Performance Testing

[0205] (1) Decellularization degree detection

[0206] The decellularized matrices prepared in Example 1, Example 2 and Example 3 were tested for indicators related to the degree of decellularization (residual cells, residual DNA), and the results are shown in Table 7.

[0207] Table 7 Decellularization degree test results of the decellularized matrix obtained in Examples 1-3

[0208]

[0209] According to Table 7, it can be seen that the decellularization of the decellularized matrix prepared by the present invention is relatively complete, reaching the common extracellular matrix decellularization reference standard mentioned in the literature [Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011, 32 (12): 3233-3243.]: (1) DNA content in the dry weight of the material <50ng / mg; (2) dsDNA fragment <200bp; (3) No visible nuclear material under DAPI or H&E stained tissue sections. It can be seen that the decellularized matrix particles provided by the present invention are completely decellularized, have a low content of immunogenic substances, and have good biological safety after entering the body.

[0210] (2) Detection of decellularized matrix components

[0211] The ECM-related components of the decellularized matrices prepared in Example 1, Example 2 and Example 3 were detected, and the results are shown in Table 8.

[0212] Table 8 Detection results of ECM-related components of the decellularized matrix prepared in Examples 1-3

[0213]

[0214]

[0215] According to Table 8, it can be seen that the decellularized matrix prepared by the present invention can better retain the ECM-related components in the decellularized matrix, including collagen, fibronectin, laminin, glycosaminoglycans and various growth factors, etc. This shows that the decellularized matrix particles prepared by the present invention retain ECM-related components, which is the material basis for endogenous induction of regeneration after implantation in the body.

[0216] (3) Characterization of decellularized matrix structure

[0217] The microstructures of the decellularized matrix particles prepared in Example 1, Example 2 and Example 3 were characterized and observed using a scanning electron microscope (SEM).

[0218] Under a low-power scanning electron microscope, it can be seen that the SIS decellularized matrix particles are of different sizes and irregular shapes; under a high-power scanning electron microscope, it can be seen that the SIS decellularized matrix particles are composed of a large number of collagen fiber bundles (with characteristic horizontal stripes), and the collagen fiber structure is intact and has a three-dimensional structure, indicating that the decellularized matrix particles prepared by the present invention have a dense structure and coarse fiber morphology of natural biomaterials. The SEM (scanning electron microscope) photo of the decellularized matrix particles prepared in Example 1 shows that the collagen fibers in the particles are aggregated together to form a natural three-dimensional structure.

[0219] (4) Decellularized matrix microparticle swelling test

[0220] The swelling degree of the decellularized matrix microparticles prepared in Example 1, Example 2, and Example 3 was tested according to the method in Appendix B of YY / T 0962-2021. The results showed that the weight of the three groups of samples after absorbing water was 6.5 times, 6.7 times, and 7.2 times the weight before absorbing water, respectively. This indicates that the decellularized matrix microparticles provided by the present invention have swelling properties and can provide immediate volume filling for the implantation site.

[0221] (5) Viscoelasticity test of acellular matrix implants

[0222] The suspensions prepared in Example 1, Example 2, Example 3 and Comparative Example 1 were freed from water and the viscous modulus and elastic modulus of the samples were tested using a rheometer. The results showed that at 1 Hz, the percentages of the viscous modulus to the elastic modulus of the samples in Example 1, Example 2, Example 3 and Comparative Example 1 were 18.42%, 17.68%, 18.89% and 8.75%, respectively. It can be seen that the decellular matrix microparticle implant provided by the present invention has suitable viscoelasticity, and the loss or viscosity modulus at 1Hz is 10% to 20% of the storage or elastic modulus, which is consistent with the viscoelasticity of natural soft tissue itself [OvijitChaudhuri1, Justin Cooper-White2, Paul A.Janmey, David J.Mooney, VivekB.Shenoy.The impact of extracellular matrix viscoelasticity on cellularbehavior.Nature.2020August; 584(7822):535–546.], and this property plays an important role in cell diffusion, growth, proliferation, migration, differentiation and tissue remodeling. In the sample of comparative example 1, the decellular matrix microparticles are first mixed with the suspending agent and then irradiated and sterilized, showing a larger elastic modulus and a smaller viscosity modulus, tending to a solid state, and its rigidity is much greater than that of natural soft tissue, suggesting that the regulation of cells after entering the body is far worse than the product of the present invention. The suspension was mixed first and then sterilized by radiation. The reason why its elastic modulus increased may be related to the cross-linking of collagen in the matrix, and the reason why its viscosity modulus decreased may be related to the degradation of polysaccharides such as glycosaminoglycans in the matrix.

[0223] (6) Testing of the dispersion uniformity and extrusion force of the suspension

[0224] For the suspension samples prepared in Examples 1-3 and Comparative Examples 1-6, the following tests were performed immediately after mixing and after the suspension was left to stand for 4 hours: (1) Manually extrude through a 27G injection needle, observe the needle clogging, and take about 0.3g of the extrudates from the front section, middle section, and rear section, respectively, accurately weigh, and determine according to the 0831 Drying loss determination method of the four general rules of the 2020 edition of the Pharmacopoeia of the People's Republic of China to calculate the solid content. Note: When extruding a 27G needle, if the needle is clogged, continue to collect the extrudate sample after replacing the needle. (2) Use a disposable 1mL sterile syringe, put on a 27G needle, and measure the pushing force according to the method in Appendix A of YY / T 0962-2021. Three samples are measured in each test group. The test results are shown in Tables 9 and 10, respectively.

[0225] Table 9 Dispersion uniformity and pushing force test data of Examples 1-3 and Comparative Examples

[0226]

[0227] Table 10 Dispersion uniformity and pushing force test data of Examples 1-3 and Comparative Examples after standing for 4 hours

[0228]

[0229]

[0230] According to Tables 9 and 10, the suspensions of Examples 1 to 3 were tested immediately after mixing and after standing for 4 hours, and the results showed that the extrusion process was smooth and the needle was not blocked. There was no obvious difference in the solid content of the front, middle and back sections of the extrudates, and the pushing force was very small, indicating that the suspensions were uniformly dispersed and stable, and had minimally invasive injectability.

[0231] The suspension of Comparative Example 1 was tested immediately after mixing and after standing for 4 hours, and both showed that the extrusion process was not smooth, the needle was clogged, and it could not be manually extruded, and the pushing force measured by the tensile tester was very large, indicating that the suspension was unevenly dispersed and not injectable.

[0232] The suspensions of Comparative Examples 2 and 4, without sufficient viscous support of sodium hyaluronate, will settle and become unevenly dispersed after standing for 4 hours even if the suspensions are evenly dispersed, indicating that sodium hyaluronate plays an important role in dispersion stability.

[0233] The suspensions of Comparative Examples 3 and 5 were tested immediately after mixing and after standing for 4 hours, and both showed that the extrusion process was not smooth and the needle was clogged. There was a significant difference in the solid content of the front, middle and back sections of the extrudates, and the pushing force was very large, indicating that the suspensions were unevenly dispersed and not minimally invasively injectable, indicating that glycerol plays a key role in dispersion uniformity.

[0234] The suspension of Comparative Example 6 was tested immediately after mixing and after standing for 4 hours, both showing that the needle was clogged, the pushing force was large, and the solid content in each section of the extrudate was different, indicating that the mixture was not dispersed evenly, which may be related to the large number of particles that were difficult to disperse.

[0235] (7) Animal experiments

[0236] The acellular matrix implant prepared in Example 1 was implanted subcutaneously into rats, and the tissue reaction and tissue regeneration were observed after 1 week, 4 weeks, 12 weeks, 16 weeks and 24 weeks of implantation.

[0237] Experimental method: The sample of Example 1 was implanted subcutaneously into rats. After 1 week, 4 weeks, 12 weeks, 16 weeks and 24 weeks of implantation, the samples (implanted samples and surrounding tissues) were taken and fixed with 10% neutral formalin. HE staining was performed as usual, and the following were observed under a microscope: the infiltration of inflammatory cells around and inside the implanted material, the proliferation of fibroblasts, the formation of collagen fibers and angiogenesis, and the filling of tissue at the implantation site.

[0238] The experimental results show that after the acellular matrix implant of Example 1 is implanted, the biocompatibility is good and there is no chronic inflammatory reaction during the entire observation period. In the first and fourth weeks of implantation, the microparticles are not degraded, and the shapes and sizes are different. The tissue filling effect is mainly exerted by the implant material. New collagen fibers can be seen in the fourth week; in the 12th and 16th weeks of implantation, while the implant material is degraded, the autologous ECM tissue regenerates and deposits at the implant site, integrates with the normal tissue, and plays a tissue filling role together; in the 24th week of implantation, the implant material has been basically degraded and replaced by orderly arranged autologous collagen fibers and new blood vessels, achieving physiological reconstruction and repair, and continuing to play a tissue filling role.

[0239] Finally, it should be understood that although various aspects of this specification are emphasized by reference to specific embodiments, it will be readily understood by those skilled in the art that these disclosed embodiments only illustrate the principles of the subject matter disclosed herein. It should also be understood that the disclosed subject matter is by no means limited to the specific methods, schemes and / or reagents described herein. Therefore, without departing from the spirit of this specification, various modifications, changes or alternative configurations can be made to the disclosed subject matter according to the teachings of this specification. The terms used herein are only used for the purpose of describing specific embodiments and are not intended to limit the scope of the present disclosure, which is defined only by the claims. In addition, the embodiments of the present disclosure are not limited to being as precise as shown and described; certain embodiments are described herein, including the best modes known to the inventors for performing the methods and devices described herein. Of course, the changes in those described embodiments will become apparent to those of ordinary skill in the art after reading the above description.

[0240] Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Additionally, this disclosure encompasses any combination of all possible variations of the above-described embodiments unless otherwise indicated herein or clearly contradicted by context.

[0241] The grouping of alternative embodiments or steps disclosed herein should not be construed as limiting. Each group member may be referred to and claimed alone or in any combination with other group members disclosed herein; it is contemplated that one or more members of a group may be included in or deleted from the group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is deemed to include the modified group, thereby satisfying all written descriptions used in the appended claims.

[0242] The following is an analysis of the above embodiments in combination with picture data:

[0243] Figure 1 It is a photograph of the decellularized matrix implant composition prepared according to the present invention (Example 1), showing that the decellularized matrix microparticles and the suspending agent are packaged separately, and the volume occupied by the microparticles in the syringe is at least larger than the volume of the suspending agent required when mixed with the suspending agent. Figure 2 and Figure 3 This is a scanning electron microscope photograph of the acellular matrix microparticles prepared in the present invention (Example 1), showing that the collagen fibers in the microparticles are aggregated together to form a three-dimensional structure, and the ECM structure is intact.

[0244] Figure 4This is a viscoelastic test graph of the decellularized matrix implant prepared by the present invention (Example 1), which shows that the product has suitable viscoelasticity, with a loss or viscosity modulus of 211.75 Pa and a storage or elastic modulus of 1149.76 Pa at 1 Hz, and a loss modulus of 18.42% of the storage modulus, which is consistent with the viscoelasticity of natural soft tissue (the loss modulus in natural soft tissue is 10% to 20% of the storage modulus).

[0245] Figure 5 and Figure 6 These are photos of suspensions prepared in the present invention (Example 1) and Comparative Example 3, showing that the particles in the sample prepared in the present invention can be evenly dispersed in the suspending agent without aggregation or sedimentation; the particles in the comparative sample have obvious aggregation, resulting in uneven mixing.

[0246] Figure 7 and Figure 8 It is a test diagram of the pushing force of the suspension prepared in the present invention (Example 1) and Comparative Example 3 through a 27G needle, showing that the sample prepared in the present invention can smoothly pass through a small diameter needle (27G) with a small pushing force, an average pushing force of less than 10N, and a maximum pushing force of less than 30N; while the comparative sample has a larger pushing force, with a maximum pushing force of more than 70N, indicating uneven dispersion.

[0247] Fig. 9 and Fig.10 The photographs of the suspensions prepared in the present invention (Example 1) and Comparative Example 2 show that the sample prepared in the present invention has cohesiveness, forms a hemispherical shape, and is not easy to flow, while the comparative sample is easy to flow and has poor cohesiveness, indicating that it is easy to shift after implantation in the body.

[0248] Fig.11 and Fig.12 The photographs are of the suspensions prepared in the present invention (Example 1) and Comparative Example 2 after standing for 4 hours, showing that the samples prepared in the present invention are mixed evenly without precipitation and stratification, while the comparative samples have obvious precipitation and stratification.

[0249] Fig.13 , Fig.14 and Fig.15 This is a particle distribution diagram of the front section, middle section and back section of the extrudate after the suspension prepared in the present invention (Example 1) was left to stand for 4 hours, showing that there is no obvious difference in the particle distribution of each section of the extrudate of the sample prepared in the present invention, and all are evenly distributed.

[0250] Fig.16The tissue sections (HE staining / MASSON staining) at different time points after the decellularized matrix implant composition prepared by the present invention (Example 1) was implanted subcutaneously in rats show that the decellularized matrix implant has good biocompatibility, does not shift or spread at the implantation site, can induce the growth of new autologous collagen fibers, and the autologous ECM tissue regenerates and deposits at the implantation site, and the filling effect is maintained for a long time.

Claims

1. An injectable acellular matrix microparticle implant for micro-plastic surgery or repair of human tissue, characterized in that: The invention is composed of decellularized matrix particles prepackaged in a syringe and a suspending agent prepackaged in a syringe or a glass bottle, which are independently packaged, sterilized separately, and mixed before use; the mixing ratio is decellularized matrix particles: suspending agent = 35mg-200mg: 1ml; the decellularized matrix is ​​derived from porcine small intestinal submucosa (SIS) and is prepared by decellularization and granulation processes; the suspending agent comprises glycerol, sodium hyaluronate, and phosphate buffer components, the glycerol concentration is 0.2%-1.0%, and the glycerol has a dispersion uniformity effect; the sodium hyaluronate concentration is 0.2%-0.5%, the molecular weight is 1 million-1.6 million Daltons, and the sodium hyaluronate has the dual effects of dispersion stability and cohesion; the pH of the suspending agent is 6.5-7.5; the osmotic pressure of the suspending agent is 270mOsmol / L-350mOsmol / L.

2. The acellular matrix microparticles according to claim 1, characterized in that The microparticles are prepared through the steps of inactivation, decellularization, freeze drying, microparticle preparation, packaging, sterilization, etc.; the microparticles are obtained by screening using any two sieves within the range of a 40-mesh sieve (aperture 380 μm) and a 300-mesh sieve (aperture 48 μm).

3. The acellular matrix microparticles according to claim 1, characterized in that The particles are provided in the form of pre-sealed syringes, and the packaging is selected from syringes that match the sterilization method of the decellularized matrix particles, such as any one of cycloolefin polymer (COP) syringes, cycloolefin copolymer (COC) syringes, and borosilicate glass syringes suitable for radiation sterilization, preferably polypropylene syringes sterilized with ethylene oxide, preferably any one of radiation sterilization and ethylene oxide sterilization; the volume occupied by the particles in the syringe is at least greater than the volume of the suspending agent required when mixed with the suspending agent.

4. The phosphate buffer according to claim 1, characterized in that It is composed of sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate and water, and plays a role in regulating pH and osmotic pressure.

5. The suspending agent according to claim 1, characterized in that Local anesthetics may be added, such as any one selected from lidocaine and procaine; active substances may be added, such as any one selected from amino acids, polypeptides, vitamins, and cytokines, or a combination thereof; anti-inflammatory agents may be added, such as any one selected from steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents, or a combination thereof; anti-allergic agents may be added, such as any one selected from diphenhydramine, promethazine, chlorpheniramine, calcium gluconate, and adrenal glucocorticoids, or a combination thereof.

6. The suspending agent according to claim 1, characterized in that It is provided in the form of a pre-sealed syringe (bottle), and its packaging is selected from a container that matches the sterilization method of the suspending agent, such as any one of a cycloolefin polymer (COP) syringe (bottle), a cycloolefin copolymer (COC) syringe (bottle), a borosilicate glass syringe (bottle), and a polypropylene syringe (bottle); the suspending agent sterilization method is a moist heat sterilization method.

7. The acellular matrix microparticle implant composition according to claim 1, characterized in that: Before use, the decellularized matrix microparticles and the suspending agent are mixed with a three-way pipe. The mixing ratio is decellularized matrix microparticles: suspending agent = 35mg-200mg: 1ml. During the mixing process, the suspending agent should be pushed toward the microparticles first, then pushed back, and the mixing should be repeated for at least 50 times.

8. A method for preparing an injectable acellular matrix microparticle implant as claimed in any one of claims 1 and 7, characterized in that: It includes the following three steps: Step 1 Preparation of decellularized matrix microparticles 1) Inactivation: Take the submucosa of the small intestine of pigs and treat it with a mixed aqueous solution of 0.5%-1.5% peracetic acid and 15%-25% ethanol under ultrasonic conditions at room temperature for 30-120 minutes for inactivation; 2) Decellularization: Wash the inactivated SIS with water for 3 times under ultrasonic conditions, divide it into small packages, freeze it quickly overnight, thaw it the next day, and repeat the freeze-thaw steps of "wash 3 times - divide it - freeze - thaw" for at least 2-4 cycles; Use a mixed aqueous solution containing 0.01%-0.05% trypsin and 0.01%-0.05% EDTA, treat at 36±2℃ for 15-60min under ultrasonic conditions, and then use PBS for ultrasonic cleaning 3 times; in a 1.5% sodium chloride hypertonic solution, treat at 36±2℃ for 15-60min under ultrasonic conditions, and then wash with water 5 times; in a 10mM-40mM NaOH aqueous solution, treat at 36±2℃ for 15-120min under ultrasonic conditions; then use water to clean with ultrasonic conditions until neutral; 3) Freeze-drying: fix the decellularized SIS sheet on a mold and freeze-dry it; 4) Preparation of microparticles: Cut the freeze-dried SIS sheet into pieces, freeze it with liquid nitrogen and then grind it, and sieve it with stainless steel sieves of different meshes to obtain decellularized matrix microparticles; the prepared decellularized matrix microparticles are obtained by sieving with any two sieves within the range of 40 mesh sieve (pore size 380 μm) and 300 mesh sieve (pore size 48 μm); 5) Packaging: Pack the decellularized matrix microparticles into syringes, wherein the volume of the microparticles in the syringe is at least larger than the volume of the suspending agent required for mixing with the suspending agent, and then seal the syringe with a stopper; 6) Sterilization: sterilize the decellularized matrix particles pre-sealed in the syringe, and select a sterilization method suitable for the decellularized matrix and its packaging, such as cobalt 60 or electron beam radiation sterilization, or ethylene oxide sterilization; Step 2 Preparation of suspending agent (a) preparing a suspending agent containing at least glycerol, sodium hyaluronate, and phosphate buffer, wherein the glycerol component has a concentration of 0.2%-1.0%; the sodium hyaluronate component has a molecular weight in the range of 1 million to 1.6 million Daltons and a concentration of 0.2%-0.5%; and the phosphate buffer can adjust the pH of the suspending agent to 6.5-7.5 and the osmotic pressure to 270-350 mOsmol / L; (b) The prepared suspending agent may be added with a local anesthetic, such as any one selected from lidocaine and procaine; an anti-inflammatory agent may be added, such as any one selected from steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents or a combination thereof; an anti-allergic agent may be added, such as any one selected from diphenhydramine, promethazine, chlorpheniramine, calcium gluconate, and adrenal glucocorticoid or a combination thereof; (c) packing the suspending agent into containers that match the sterilization method of the suspending agent, such as any one of cyclic olefin polymer (COP) syringes (bottles), cyclic olefin copolymer (COC) syringes (bottles), borosilicate glass syringes (bottles), and polypropylene syringes (bottles), and sealing them with stoppers; (d) sterilizing the suspension pre-sealed in the syringe (bottle) with moist heat; Step three: the decellularized matrix microparticles and the suspending agent are packaged independently, sterilized separately, and fully mixed with a three-way pipe before use; the injectable decellularized matrix microparticle implant prepared by mixing has good viscoelasticity and plasticity, and does not shift in the body after injection.

9. The use of an injectable acellular matrix microparticle implant according to claim 1, characterized in that: Microinjection is used for medical purposes such as cosmetic surgery, oral and dental plastic surgery, and cartilage defect repair; the skin plastic surgery uses include, on the one hand, injection into the deep dermis to subcutaneous for the repair of wrinkles (such as nasolabial folds) and various skin surface depressions, on the other hand, injection into the superficial to middle layers of the skin for the repair of fine lines around the corners of the eyes, forehead, back of the hands, and neck, and on the other hand, injection into deep tissues such as the fascia layer to restore the facial contour to a firm, bony support and shape a three-dimensional bone phase (such as rhinoplasty); the microinjection refers to injection needles of 27G and 30G.

Citation Information

Cited By

  • Implant and preparation method thereof

    CN119367615A

  • Preparation process of acellular matrix particles

    CN120267899A

  • Facial filling and skin improving compound preparation based on acellular matrix as well as preparation method and application of facial filling and skin improving compound preparation

    CN122141004A